Thu, 13 Nov 2025
Brenntag Signs Exclusive Distribution Deal with ArcticZymes for Bioprocessing Enzymes
Brenntag, the global market leader in chemicals and ingredients distribution, announced a new and exclusive distribution agreement with ArcticZymes AS on the salt-active nucleases: SAN HQ, SAN-HQ GMP, M-SAN HQ, M-SAN HQ GMP, developed for the efficient removal of nucleic acids in gene therapy, vaccine production and other bioprocessing workflows.
The biopharmaceutical industry is growing rapidly worldwide each year, driven by the fast expansion of gene therapy, cell therapy, and the development of biopharmaceutical vaccines. This rapid growth creates new challenges for customers, which are being addressed by the strategic partnership between Brenntag Pharma and ArcticZymes.
By using Brenntag's well-established distribution channels and broad market access, a wider range of customers can access ArcticZymes pioneering endonucleases, meeting the dynamic expansion of the biopharma market.
At the same time, Brenntag Pharma gains access to important nuclease products that play a crucial role in downstream bioprocessing, as well as to ArcticZymes' expertise and strong team to drive future projects. Through this collaboration, biopharmaceutical customers will benefit from access to ArcticZymes' salt-active nucleases, which help reduce processing costs and increase product yield.
Unlike traditional enzymes, SAN HQ and M-SAN HQ maintain strong activity under physiological and high-salt conditions, essential for effective chromatin digestion and improved product purity.
- M-SAN HQ: Optimized for 125–200 mM NaCl; ideal for direct use in cell media and a drop-in replacement for traditional nucleases.
- SAN HQ: Active even above 300 mM NaCl; perfect for de-aggregation and high-yield purification workflows.
Both enzymes are also available in GMP grade, reducing the challenge of moving therapies from pilot scale into manufacture.
Joakim Rehné, Regional President Brenntag Pharma EMEA says: “Our partnership with ArcticZymes for SAN HQ and M-SAN HQ marks a milestone in Brenntag’s commitment to the biopharmaceutical industry. By expanding our portfolio with high-quality enzymes, we support our customers from the early research phase through to full commercialization.”
Paul Blackburn, Chief Commercial Officer from ArcticZymes, adds: “We’re pleased to partner with Brenntag as our new European distributor. This collaboration marks an important milestone in advancing our channel strategy and broadening access to ArcticZymes’ pioneering salt-active nucleases. Sharing our dedication to quality, scientific excellence, and customer focus, Brenntag is the ideal partner to complement our sales organization and strengthen customer engagement across the region. Together, we’ll better support our expanding vaccine and gene therapy customer base.”
{{model.votes}}
Featured Recruiters
